Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson’s disease: possible involvement of different binding sites at the PPARγ receptor

@inproceedings{Garca2018BenefitsOV,
  title={Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson’s disease: possible involvement of different binding sites at the PPARγ receptor},
  author={Concepci{\'o}n Hern{\'a}ndez Garc{\'i}a and Mar{\'i}a G{\'o}mez-Ca{\~n}as and Sonia Burgaz and Bel{\'e}n Palomares and Yolanda G{\'o}mez-G{\'a}lvez and Cristina Palomo-Garo and Sara Campo and Joel Ferrer-Hern{\'a}ndez and Carolina Pavicic and Carmen Luz Navarrete and Maria Luz Bellido and Mois{\'e}s Garc{\'i}a-Arencibia and M. Ruth Pazos and Eduardo Mu{\~n}oz and Javier Fern{\'a}ndez-Ruiz},
  booktitle={Journal of Neuroinflammation},
  year={2018}
}
Neuroprotection with cannabinoids in Parkinson’s disease (PD) has been afforded predominantly with antioxidant or anti-inflammatory cannabinoids. In the present study, we investigated the anti-inflammatory and neuroprotective properties of VCE-003.2, a quinone derivative of the non-psychotrophic phytocannabinoid cannabigerol (CBG), which may derive its activity at the peroxisome proliferator-activated receptor-γ (PPARγ). The compound is also an antioxidant. We evaluated VCE-003.2 in an in vivo… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 12 times over the past 90 days. VIEW TWEETS
1 Citations
55 References
Similar Papers

Citations

Publications citing this paper.

References

Publications referenced by this paper.
Showing 1-10 of 55 references

Similar Papers

Loading similar papers…